Metastatic Pancreatic Cancer
Conditions
Brief summary
This is an open-label Phase 2 Pilot study to evaluate Disulfiram + Copper Gluconate in patients metastatic pancreatic cancer whose CA-19-9 levels rise while receiving nab-paclitaxel (Abraxane) plus gemcitabine (Gemzar) or FOLFIRINOX or single-agent gemcitabine (Gemzar). Patient must have received a minimum of 8 weeks of treatment and have rising CA-19-9 levels in the absence of radiographic evidence of progression.
Detailed description
This study has 3 arms with 5 patients enrolled in each of the three arms. The three treatment arms are based upon whether the patient has previously received Abraxane-Gemcitabine or FOLFIRINOX or single-agent Gemcitabine without radiographic evidence of disease progression for a minimum of 8 weeks , based on the investigator's opinion, but with a rising Carbohydrate antigen 19-9 (CA 19-9) levels. Rising CA 19-9 is defined as an increased over baseline of \> 20% in two consecutive time points within 8 days of each other. Study sites will provide all chemotherapy for patients participating in the study as a standard of care. DSF/Cu (Disulfiram + Copper Gluconate) will be provided by the Sponsor and shipped from the Sponsor's central depot to the study sites. Sufficient amounts of DSF/Cu will be available at the study site prior to enrolling patients in the study.
Interventions
DIAGNOSTIC_TESTSafety Laboratories
Complete blood cell count (CBC) w Differential, comprehensive metabolic panel (CMP), Prothrombin time/international normalized ratio (PT/INR) Activated Partial Thromboplastin Time (aPTT), Urinalysis
OTHERAE Assessment
Assessment of Adverse Events (AE)
OTHERPhysical Exam
Physical Exam, Weight, Vital Signs, Eastern Cooperative Oncology Group (ECOG) Performance Status
OTHERConcomitant Medication Review
Prior and Concomitant Medication Review
DIAGNOSTIC_TESTTumor Imaging
Tumor CT or MRI
DRUGnab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate
nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
DRUGFOLFIRINOX regimen Plus Disulfiram/Copper Gluconate
FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
DRUGSingle-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate
Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
Sponsors
Cantex Pharmaceuticals
HonorHealth Research Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 105 Years
Healthy volunteers
No
Inclusion criteria
1. Patients must have histologically confirmed adenocarcinoma of the pancreas that is metastatic and for which potential curative measures, such as resection of an isolated metastasis, are not available. Patients with islet cell neoplasms are excluded. 2. Patient should currently be receiving a chemotherapy regimen comprising FOLFIRINOX or Abraxane-Gemcitabine or single-agent Gemcitabine as front-line treatment for metastatic disease. Patients who have had chemotherapy in the adjuvant or neoadjuvant setting are eligible. 3. Patients must have previously received a minimum of 8 weeks of therapy with Abraxane-Gemcitabine or FOLFIRINOX or single-agent Gemcitabine without radiographic evidence of disease progression based on the investigator's opinion, but a rising CA 19-9 level, and still be undergoing treatment with Abraxane-Gemcitabine or FOLFIRINOX or single-agent Gemcitabine. Increased CA 19-9 is defined as an increased over baseline of \> 20% in two consecutive time points within 8 days of each other. 4. Patient has one or more metastatic tumors measurable by CT scan. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>20 mm with conventional techniques or as \>10 mm with spiral CT scan. 5. Male or non-pregnant and non-lactating female and ≥ 18 to ≤ 80 years of age. 6. Patient has adequate biological parameters as demonstrated by the following blood counts at Screening (obtained ≤ 14 days prior to enrollment) and at Baseline-Day 0: Absolute neutrophil count (ANC) ≥ 1.5 × 109/L; Platelet count ≥ 100,000/mm3 (100 × 109/L); Hemoglobin (Hgb) ≥ 9 g/dL. 7. Patient has the following blood chemistry levels at Screening (obtained ≤ 14 days prior to enrollment) and at Baseline-Day 0: * aspartate aminotransferase (AST) (SGOT), Alanine Transaminase (ALT) (SGPT) ≤ 2.5 × upper limit of normal range (ULN), unless liver metastases are present, then ≤ 5 × ULN is allowed. Total bilirubin ≤ 1.5 × ULN. * Serum creatinine \< 1.5X ULN or estimated creatinine clearance of \> 60 mL/min (per Cockroft-Gault formula) 8. Patient has ECOG performance status from 0 to ≤ 1. 9. Patient has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent Form (ICF) prior to participation in any study-related activities.
Exclusion criteria
1. Patient has brain metastases. 2. Patient has experienced an increase of ECOG to \> 1 between Screening and enrollment. 3. QTc \> 480 msec if patient receiving oxaliplatin-containing regimen. 4. Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy. 5. Patient has a history of allergy or hypersensitivity to any of the study drugs, their pharmaceutical class or any of their excipients. The patient exhibits any of the events outlined in the Contraindications or Special Warnings and Precautions sections of Gemcitabine or Abraxane ® Prescribing Information package inserts or on the Investigator's Brochure for DSF/Cu. 6. Patient has a concomitant serious medical or psychiatric illness that, in the opinion of the investigator, could compromise the patient's safety or the study data integrity. 7. Patient is enrolled in any other clinical protocol or investigational trial involving administration of antineoplastic compounds for the treatment of metastatic pancreatic cancer. 8. Patient is unwilling or unable to comply with study procedures. 9. Abraxane is metabolized by CYP2C8 and CYP3A4. Co-administration of substrates, inhibitors of CYP2C8 (see Appendix C) and/or CYP3A4 (see Appendix D) with Abraxane is not allowed. The following medications and substances are not allowed during the study: ritonavir, saquinavir, indinavir, nelfinavir, rifampicin, carbamazepine, phenytoin, efiravenz, or nerivapine, grapefruit (juice or seeds) or some herbals like St. John's wort.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| CA19-9 Plasma Level | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Change in plasma CA19-9 level (at least 30%) from baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete Tumor Response | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Complete response rate as defined by CT scan using RECIST 1.1 criteria |
| Partial Response | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Partial response as defined by CT scan using RECIST 1.1 criteria |
| Stable Disease | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Complete response as defined by CT scan using RECIST 1.1 criteria |
| Overall Response Rate | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Overall response rate as defined by CT scan using RECIST 1.1 criteria |
| Serum Albumin | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Change in serum albumin level as a result of treatment |
| Body Weight | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Change in body weight as a result of treatment |
| Muscle Area at the L3 Level - Optional | From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Change in muscle area at the L3 level using CT scan. Only is L3 is visualized with normally scheduled standard of care CT Scan |
| Incidence of Toxicities | From date of enrollment until the date of follow-up, 30 days after last treatment | Physical exam and laboratory testing will be completed and toxicity grading assessed and documented using CTCAE version 4.0 |
| Overall Survival | From date of enrollment until date of death assessed up to 100 months | The length of time from the start of treatment that patients are still alive |
Other
| Measure | Time frame | Description |
|---|---|---|
| Disulfiram/Copper Gluconate Serum Levels - Area Under the Curve (AUC) | Day 0 (pre-Cycle 1 Day 1) at pre-dose, 2 hours, 4 hours, 24 hours and 4 hours post-dose Cycle 1 Day 7 | Optional Day 0 (pre-Cycle 1 Day 1) at pre-dose, 2 hours, 4 hours, 24 hours and 4 hours post-dose Cycle 1 Day 7 |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Nab-Paclitaxel/Gemcitabine + DSF/Cu Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with Nab-Paclitaxel-Gemcitabine with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
Safety Laboratories: CBC w Differential, CMP, PT/INR, aPTT, Urinalysis
AE Assessment: Assessment of Adverse Events
Physical Exam: Physical Exam, Weight, Vital Signs, ECOG Performance Status
Concomitant Medication Review: Prior and Concomitant Medication Review
Tumor Imaging: Tumor CT or MRI
nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate: nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate: FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing | 1 |
| FOLFIRINOX +DSF/Cu Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with FOLFIRINOX and with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
Safety Laboratories: CBC w Differential, CMP, PT/INR, aPTT, Urinalysis
AE Assessment: Assessment of Adverse Events
Physical Exam: Physical Exam, Weight, Vital Signs, ECOG Performance Status
Concomitant Medication Review: Prior and Concomitant Medication Review
Tumor Imaging: Tumor CT or MRI
nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate: nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate: FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing | 0 |
| Single-Agent Gemcitabine +DSF/Cu Subjects with metastatic adenocarcinoma of the pancreas who have received a minimum of 8 weeks of treatment with Single-Agent Gemcitabine and with rising CA 19-9 levels in the absence of radiographic evidence of progression will continue to receive treatment with addition of Disulfiram+Copper Gluconate until disease progression.
Safety Laboratories: CBC w Differential, CMP, PT/INR, aPTT, Urinalysis
AE Assessment: Assessment of Adverse Events
Physical Exam: Physical Exam, Weight, Vital Signs, ECOG Performance Status
Concomitant Medication Review: Prior and Concomitant Medication Review
Tumor Imaging: Tumor CT or MRI
nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate: nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate: FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing | 0 |
| Total | 1 |
Baseline characteristics
| Characteristic | Nab-Paclitaxel/Gemcitabine + DSF/Cu | Total |
|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized African American | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Alaska Native | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized American Indian | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Caucasian | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Native Hawaiian | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Not Reported | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Pacific Rim | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Unknown | 0 Participants | 0 Participants |
| Region of Enrollment United States | 1 participants | 1 participants |
| Sex: Female, Male Female | 1 Participants | 1 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 1 | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 1 / 1 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 1 / 1 | 0 / 0 | 0 / 0 |
Outcome results
Primary
CA19-9 Plasma Level
Change in plasma CA19-9 level (at least 30%) from baseline
Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Population: One patient was treated. This patient was on study for 6 weeks and ended trial participation due to progressive disease.
Secondary
Body Weight
Change in body weight as a result of treatment
Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Population: One patient was treated. This patient was on study for 6 weeks and ended trial participation due to progressive disease.
Secondary
Complete Tumor Response
Complete response rate as defined by CT scan using RECIST 1.1 criteria
Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Population: One patient was treated. This patient was on study for 6 weeks and ended trial participation due to progressive disease.
Secondary
Incidence of Toxicities
Physical exam and laboratory testing will be completed and toxicity grading assessed and documented using CTCAE version 4.0
Time frame: From date of enrollment until the date of follow-up, 30 days after last treatment
Population: One patient was treated. This patient was on study for 6 weeks and ended trial participation due to progressive disease.
Secondary
Muscle Area at the L3 Level - Optional
Change in muscle area at the L3 level using CT scan. Only is L3 is visualized with normally scheduled standard of care CT Scan
Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Population: One patient was treated. This patient was on study for 6 weeks and ended trial participation due to progressive disease.
Secondary
Overall Response Rate
Overall response rate as defined by CT scan using RECIST 1.1 criteria
Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Population: One patient was treated. This patient was on study for 6 weeks and ended trial participation due to progressive disease.
Secondary
Overall Survival
The length of time from the start of treatment that patients are still alive
Time frame: From date of enrollment until date of death assessed up to 100 months
Population: One patient was treated. This patient was on study for 6 weeks and ended trial participation due to progressive disease.
Secondary
Partial Response
Partial response as defined by CT scan using RECIST 1.1 criteria
Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Population: One patient was treated. This patient was on study for 6 weeks and ended trial participation due to progressive disease.
Secondary
Serum Albumin
Change in serum albumin level as a result of treatment
Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Population: One patient was treated. This patient was on study for 6 weeks and ended trial participation due to progressive disease.
Secondary
Stable Disease
Complete response as defined by CT scan using RECIST 1.1 criteria
Time frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Population: One patient was treated. This patient was on study for 6 weeks and ended trial participation due to progressive disease.
Other Pre-specified
Disulfiram/Copper Gluconate Serum Levels - Area Under the Curve (AUC)
Optional Day 0 (pre-Cycle 1 Day 1) at pre-dose, 2 hours, 4 hours, 24 hours and 4 hours post-dose Cycle 1 Day 7
Time frame: Day 0 (pre-Cycle 1 Day 1) at pre-dose, 2 hours, 4 hours, 24 hours and 4 hours post-dose Cycle 1 Day 7